NYSEMKT: LCTX
Lineage Cell Therapeutics Inc Stock Ownership - Who owns Lineage Cell Therapeutics?

Insider buying vs selling

Have Lineage Cell Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Brian M. CulleyPresident and CEO2026-03-1215,000$1.63
$24.38kBuy
Brian M. CulleyPresident and CEO2026-02-1112,869$1.80
$23.16kSell
George A. Samuel IiiGeneral Counsel and Secretary2026-02-112,502$1.80
$4.50kSell
Brian M. CulleyPresident and CEO2025-12-19334$1.68
$561.12Sell
George A. Samuel IiiGeneral Counsel and Secretary2025-12-1965$1.68
$109.20Sell

1 of 1

LCTX insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when LCTX insiders and whales buy or sell their stock.

LCTX Shareholders

What type of owners hold Lineage Cell Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Broadwood Partners LP32.70%81,531,259$105.18MInsider
Broadwood Capital Inc19.88%49,560,992$63.93MInstitution
Neal C. Bradsher19.06%47,515,269$61.29MInsider
Alfred D. Kingsley4.15%10,344,637$13.34MInsider
Vanguard Capital Management LLC3.34%8,318,685$10.73MInstitution
Defender Capital LLC2.70%6,729,599$8.68MInstitution
Millennium Management LLC2.23%5,561,374$7.17MInstitution
Raffles Associates LP2.15%5,362,788$6.92MInstitution
George Karfunkel2.00%4,982,217$6.43MInsider
Fifth Third Bancorp1.85%4,600,000$5.93MInstitution

1 of 3

LCTX vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
LCTX42.24%57.76%Net SellingNet Buying
TENX72.65%27.35%Net Buying
IVVD71.04%28.96%Net Selling
NAUT36.88%63.12%Net BuyingNet Buying
RZLT44.44%55.56%Net BuyingNet Selling

Lineage Cell Therapeutics Stock Ownership FAQ

Who owns Lineage Cell Therapeutics?

Lineage Cell Therapeutics (NYSEMKT: LCTX) is owned by 44.80% institutional shareholders, 61.26% Lineage Cell Therapeutics insiders, and 0.00% retail investors. Broadwood Partners LP is the largest individual Lineage Cell Therapeutics shareholder, owning 81.53M shares representing 32.70% of the company. Broadwood Partners LP's Lineage Cell Therapeutics shares are currently valued at $107.62M.

If you're new to stock investing, here's how to buy Lineage Cell Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.